Edition:
United States

Inovio Pharmaceuticals Inc (INO.O)

INO.O on Nasdaq

2.44USD
11:03am EDT
Change (% chg)

$0.01 (+0.62%)
Prev Close
$2.43
Open
$2.42
Day's High
$2.45
Day's Low
$2.41
Volume
46,394
Avg. Vol
950,924
52-wk High
$6.30
52-wk Low
$2.15

Latest Key Developments (Source: Significant Developments)

Inovio Pharmaceuticals Reports Q2 Loss Per Share $0.30
Thursday, 8 Aug 2019 04:05pm EDT 

Aug 8 (Reuters) - Inovio Pharmaceuticals Inc ::INOVIO PHARMACEUTICALS REPORTS 2019 SECOND QUARTER FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.30.Q2 REVENUE $136,000.Q2 REVENUE ESTIMATE $5.7 MILLION -- REFINITIV IBES DATA.Q2 EARNINGS PER SHARE ESTIMATE $-0.27 -- REFINITIV IBES DATA.  Full Article

Inovio Pharma Expects To Incur A Personnel-Related Restructuring Charge Of About $2.3 Mln To Be Incurred Primarily In Q3 Of 2019
Tuesday, 16 Jul 2019 04:57pm EDT 

July 16 (Reuters) - Inovio Pharmaceuticals Inc ::INOVIO PHARMACEUTICALS INC - EXPECTS TO INCUR A PERSONNEL-RELATED RESTRUCTURING CHARGE OF ABOUT $2.3 MILLION TO BE INCURRED PRIMARILY IN Q3 OF 2019.  Full Article

Inovio Pharma Appoints Jacqueline Shea As Chief Operating Officer
Tuesday, 12 Mar 2019 08:00am EDT 

March 12 (Reuters) - Inovio Pharmaceuticals Inc ::INOVIO APPOINTS CHIEF OPERATING OFFICER; ANNOUNCES STRATEGIC MANAGEMENT CHANGES.APPOINTMENT OF JACQUELINE E. SHEA, PHD, AS INOVIO'S CHIEF OPERATING OFFICER (COO) AND EXECUTIVE VICE PRESIDENT.SHEA REPLACES DR. NIRANJAN Y. SARDESAI WHO NOW SERVES AS CHIEF EXECUTIVE OFFICER OF GENEOS THERAPEUTICS.MARK BAGARAZZI, FORMERLY CHIEF MEDICAL OFFICER, HAS LEFT COMPANY.  Full Article

Inovio Pharma Prices $65 Mln Convertible Senior Notes Offering
Thursday, 14 Feb 2019 07:00am EST 

Feb 14 (Reuters) - Inovio Pharmaceuticals Inc ::INOVIO PHARMACEUTICALS PRICES $65.0 MILLION CONVERTIBLE SENIOR NOTES OFFERING.INOVIO PHARMACEUTICALS INC - PRICING OF ITS OFFERING OF $65.0 MILLION AGGREGATE PRINCIPAL AMOUNT OF 6.50% CONVERTIBLE SENIOR NOTES DUE 2024.  Full Article

Inovio Announces Appointments To Its Board Of Directors
Thursday, 3 Jan 2019 08:00am EST 

Jan 3 (Reuters) - Inovio Pharmaceuticals Inc ::INOVIO ANNOUNCES APPOINTMENTS TO ITS BOARD OF DIRECTORS.INOVIO PHARMACEUTICALS INC - SIMON X. BENITO, DIRECTOR SINCE 2003, NAMED CHAIRMAN OF BOARD.INOVIO PHARMACEUTICALS INC - LOTA ZOTH, FORMER MEDIMMUNE CFO, JOINS BOARD.INOVIO PHARMACEUTICALS INC - BENITO, FORMER MERCK VACCINES EXECUTIVE, HAS BEEN APPOINTED CHAIRMAN REPLACING AVTAR DHILLON WHO IS RETIRING.  Full Article

Inovio Pharmaceuticals Q3 Loss Per Share $0.27
Thursday, 8 Nov 2018 04:05pm EST 

Nov 8 (Reuters) - Inovio Pharmaceuticals Inc ::INOVIO PHARMACEUTICALS REPORTS 2018 THIRD QUARTER FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.27.Q3 EARNINGS PER SHARE VIEW $-0.30 -- THOMSON REUTERS I/B/E/S.TOTAL REVENUE WAS $2.0 MILLION FOR THREE MONTHS ENDED SEPTEMBER 30, 2018, COMPARED TO $2.6 MILLION.  Full Article

Inovio Pharmaceuticals Inc Files For Mixed Shelf Offering Of Up To $250 Mln
Friday, 25 May 2018 04:39pm EDT 

May 25 (Reuters) - Inovio Pharmaceuticals Inc ::INOVIO PHARMACEUTICALS INC FILES FOR MIXED SHELF OFFERING OF UP TO $250 MILLION - SEC FILING.  Full Article

Inovio Pharmaceuticals, Parker Institute For Cancer Immunotherapy Establish Clinical Development Collaboration To Evaluate Novel Cancer Immunotherapy Combinations
Tuesday, 9 Jan 2018 08:00am EST 

Jan 9 (Reuters) - Inovio Pharmaceuticals Inc ::INOVIO PHARMACEUTICALS AND THE PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY ESTABLISH CLINICAL DEVELOPMENT COLLABORATION TO EVALUATE NOVEL CANCER IMMUNOTHERAPY COMBINATIONS.INOVIO PHARMACEUTICALS - UNDER AGREEMENT, PARKER INSTITUTE WILL HAVE RESPONSIBILITY FOR CLINICAL STUDY EXECUTION.INOVIO PHARMACEUTICALS - WILL PROVIDE FINANCIAL CONTRIBUTIONS IF CO'S PRODUCT(S) STUDIED UNDER COLLABORATION REACHES INITIATION OF PHASE 3 STUDY.  Full Article

Inovio Receives Milestone Payment From Medimmune
Monday, 8 Jan 2018 08:00am EST 

Jan 8 (Reuters) - Inovio Pharmaceuticals Inc ::INOVIO RECEIVES MILESTONE PAYMENT FROM MEDIMMUNE AS MEDI0457 AND CHECKPOINT INHIBITOR COMBINATION TRIAL IN HEAD AND NECK SQUAMOUS CELL CANCER ADVANCES TO PHASE 2.  Full Article

Inovio Announces Analysis Of VGX-3100 Phase 2b Data
Wednesday, 29 Nov 2017 08:00am EST 

Nov 29 (Reuters) - Inovio Pharmaceuticals Inc ::INOVIO’S FURTHER ANALYSIS OF VGX-3100 PHASE 2B DATA REVEALS IMMUNE CORRELATES AND BIOMARKER SIGNATURES THAT PREDICTED CLINICAL EFFICACY.INOVIO PHARMACEUTICALS - ‍IN 2018, CO TO INITIATE PHASE 2 "PROOF-OF-CONCEPT" STUDY FOR TREATMENT OF HIGH GRADE ANAL NEOPLASIA.  Full Article